WDR21B Inhibitors
WDR21B inhibitors represents a group of compounds designed to target and modulate the activity of the WDR21B protein. WDR21B, short for WD repeat-containing protein 21B, is a member of the WD repeat protein family, characterized by its repeated sequence of about 40-60 amino acids, forming a beta-propeller structure. These inhibitors are meticulously engineered to specifically interact with WDR21B, influencing its function within cellular processes. The primary goal of these compounds is to disrupt the normal protein-protein interactions or binding capabilities of WDR21B, thereby altering its role in various cellular pathways.
The structural design of WDR21B inhibitors is intricately crafted to fit into the binding sites or domains of WDR21B, hindering its normal physiological interactions. This interference may lead to downstream effects on cellular processes such as signal transduction, gene expression, or protein degradation. The rational design of these inhibitors involves a deep understanding of the three-dimensional structure of WDR21B and its functional domains. Researchers employ various computational and experimental techniques to identify and optimize compounds that can selectively bind to WDR21B. As part of ongoing investigations in the field of molecular pharmacology, WDR21B inhibitors contribute to the broader exploration of protein modulation for potential applications in research and discovery within the realm of cellular biology.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent non-selective inhibitor of protein kinases. By inhibiting a broad range of kinases, it can affect various signaling pathways that may indirectly reduce the functional activity of WDR21B, especially if WDR21B is a part of kinase signaling cascades. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, LY294002 disrupts the PI3K/AKT signaling pathway, which could indirectly lead to reduced activity of WDR21B if it is involved in this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that disrupts the mTOR signaling pathway. This pathway is essential for cell growth and autophagy, and inhibition of mTOR can lead to indirect effects on proteins like WDR21B that may be regulated by this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which prevents the activation of the downstream kinase ERK in the MAPK pathway. If WDR21B is modulated by the MAPK signaling cascade, PD98059 could indirectly decrease its activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase. The p38 MAP kinase pathway is involved in inflammatory responses and stress stimuli. By inhibiting this pathway, SB203580 could indirectly affect WDR21B function if it is linked to this signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). By blocking JNK signaling, SP600125 can affect cellular processes such as apoptosis and inflammation, potentially reducing WDR21B activity if it interacts with JNK-regulated pathways. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $148.00 $597.00 | 75 | |
NSC23766 is a specific inhibitor of the Rac1 GTPase. It interferes with the signaling pathways that involve Rac1, potentially impacting WDR21B activity if WDR21B is associated with Rac1-mediated signaling events. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a selective inhibitor of the Rho-associated protein kinase (ROCK). ROCK is involved in regulating cell shape, motility, and contraction. Inhibition of ROCK could lead to changes in WDR21B activity if WDR21B is part of the pathway regulated by ROCK. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a MEK inhibitor that can block the MAPK/ERK pathway. If WDR21B is regulated by or interacts with components of this pathway, U0126 could indirectly decrease WDR21B's functional activity. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132 is a proteasome inhibitor that prevents the degradation of ubiquitinated proteins. If the stability or degradation of WDR21B is regulated by the ubiquitin-proteasome system, MG-132 might lead to an indirect reduction in WDR21B activity through accumulation of regulatory proteins. | ||||||